Fig. 2From: Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutationDistribution of TP53 mutation (A) and EGFR mutation (B) sites in patients with a co-mutationBack to article page